Mari Cruz Rodríguez-Oroz

Learn More
UNLABELLED Dopaminergic depletion in the nigrostriatal system is the neurochemical hallmark of Parkinson's disease (PD). Although numerous efforts have been made to determine the evolution of dopaminergic depletion in PD, "in vivo" data concerning the stages of this process are still scarce. We evaluated 6-[18F]-fluoro-l-DOPA ((18)F-DOPA) and(More)
The recordings of local field potentials in the subthalamic nucleus in patients with Parkinson's disease (PD), carried out through the stimulators implanted to treat the motor symptoms of the disease, show a prominent basal ("off") activity in the beta range, which is attenuated after dopaminergic therapy. A recent study described improvement of(More)
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting millions of people. Genome-wide association studies (GWAS) have found >25 genetic risk factors and at least 15 loci directly associated with PD. Recent advances in new next-generation DNA sequencing technologies, such as the semiconductor-based Ion Torrent platform,(More)
BACKGROUND Parkinson's disease (PD) is a progressive neurodegenerative disorder causing motor and non-motor symptoms that can affect independence, social adjustment and the quality of life (QoL) of both patients and caregivers. Studies designed to find diagnostic and/or progression biomarkers of PD are needed. We describe here the study protocol of(More)
Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression Erratum After publication of the original article [1], it has come to the authors'(More)
Resumen Los autores realizan una revisión crítica de la estimulación del núcleo subtalámico (NST) en la enfermedad de Parkinson (EP) a largo plazo (3-5 años). La estimulación del NST produce una mejoría significativa de la parte motora de la escala UPDRS (Unified Parkinson Disease Rating Scale) sin medi-cación a los 3-5 años de la cirugía. Los resultados(More)
  • 1